These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 8093494

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Case report: Neuroleptic malignant syndrome and diagnostic difficulties].
    Khouri C, Planès S, Logerot S, Villier C, Mallaret M.
    Encephale; 2016 Jun; 42(3):277-80. PubMed ID: 26923996
    [Abstract] [Full Text] [Related]

  • 3. Neuroleptic malignant syndrome due to olanzapine.
    Hall KL, Taylor WH, Ware MR.
    Psychopharmacol Bull; 2001 Jun; 35(3):49-54. PubMed ID: 12397878
    [Abstract] [Full Text] [Related]

  • 4. [Malignant neuroleptic syndrome. A review of epidemiology, risk factors, diagnosis, differential diagnosis and pathogenesis of MNS].
    Andreassen MD, Pedersen S.
    Ugeskr Laeger; 2000 Mar 06; 162(10):1366-70. PubMed ID: 10745673
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Neuroleptic malignant syndrome. Case reports].
    Berardi D, Troia M, Veronesi L, Ferrari G.
    Minerva Psichiatr; 1994 Dec 06; 35(4):199-219. PubMed ID: 7861943
    [Abstract] [Full Text] [Related]

  • 7. Neuroleptic malignant syndrome.
    Kornhuber J, Weller M.
    Curr Opin Neurol; 1994 Aug 06; 7(4):353-7. PubMed ID: 7952245
    [Abstract] [Full Text] [Related]

  • 8. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management.
    Perry PJ, Wilborn CA.
    Ann Clin Psychiatry; 2012 May 06; 24(2):155-62. PubMed ID: 22563571
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Neuroleptic malignant syndrome: guidelines for treatment and reinstitution of neuroleptics.
    Olmsted TR.
    South Med J; 1988 Jul 06; 81(7):888-91. PubMed ID: 2899358
    [Abstract] [Full Text] [Related]

  • 13. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations.
    Picard LS, Lindsay S, Strawn JR, Kaneria RM, Patel NC, Keck PE.
    Pharmacotherapy; 2008 Apr 06; 28(4):530-5. PubMed ID: 18363536
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recurrence of neuroleptic malignant syndrome.
    Susman VL, Addonizio G.
    J Nerv Ment Dis; 1988 Apr 06; 176(4):234-41. PubMed ID: 2895164
    [Abstract] [Full Text] [Related]

  • 16. Pathogenesis and treatment of neuroleptic malignant syndrome.
    Ebadi M, Pfeiffer RF, Murrin LC.
    Gen Pharmacol; 1990 Apr 06; 21(4):367-86. PubMed ID: 1974219
    [Abstract] [Full Text] [Related]

  • 17. Neuroleptic malignant syndrome: a dangerous complication of neuroleptic therapy.
    Byrd C.
    J Neurosci Nurs; 1993 Feb 06; 25(1):62-5. PubMed ID: 8445278
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [The neuroleptic malignant syndrome (NMS). A report of a clinical case with a protracted and recurrent course. A review of the literature].
    Marelli A, Bodini P, Dizioli P, Chiodelli G, Guarneri M, Boldori L.
    Minerva Med; 1996 Feb 06; 87(1-2):45-51. PubMed ID: 8610025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.